Who are Dexilant's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Nexium, Protonix, Protonix, Pantoprazole Sodium, Aciphex, Prevacid.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dexlansoprazole.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Dexilant — Competitive Intelligence Brief

Dexilant (DEXLANSOPRAZOLE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Proton Pump Inhibitor [EPC]. Area: Pain.

marketed Proton Pump Inhibitor [EPC] (H+, K+)-ATPase Pain Small molecule Live · refreshed every 30 min

Target snapshot

Dexilant (DEXLANSOPRAZOLE) — Takeda. Dexlansoprazole inhibits gastric acid secretion by blocking the (H+, K+)-ATPase enzyme, known as the proton pump, in gastric parietal cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Dexilant TARGET	DEXLANSOPRAZOLE	Takeda	marketed	Proton Pump Inhibitor [EPC]	(H+, K+)-ATPase	2009-01-01
Nexium	esomeprazole	AstraZeneca	marketed	Proton pump inhibitor (PPI)	Potassium-transporting ATPase	2001-02-20
Protonix	pantoprazole	Generic (originally Byk Gulden/Altana/Nycomed)	marketed	Proton pump inhibitor (PPI)	ATP-binding cassette sub-family G member 2, Fatty acid synthase, Multidrug and toxin extrusion protein 1	2000-02-02
Protonix	Pantoprazole Sodium	Baxter	marketed	Proton pump inhibitor (PPI)	(H+, K+)-ATPase enzyme system	2000-01-01
Pantoprazole Sodium	Pantoprazole Sodium	Pfizer	marketed	Proton pump inhibitor (PPI)	(H+, K+)-ATPase enzyme	2000-01-01
Aciphex	rabeprazole	Waylis	marketed	Proton Pump Inhibitor	Potassium-transporting ATPase	1999-01-01
Prevacid	lansoprazole	Generic (originally Takeda)	marketed	Proton pump inhibitor (PPI)	ATP-binding cassette sub-family G member 2, Cytochrome P450 2C19, Cytosolic endo-beta-N-acetylglucosaminidase	1995-05-10

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-06-07 — Pantoprazole Sodium · 7544370 · US
2026-12-07 — Pantoprazole Sodium · 7544370*PED · US
2036-04-21 — Prevacid · 11077055 · Formulation · US
2036-04-21 — Prevacid · 11986554 · Formulation · US

Sponsor landscape (Proton Pump Inhibitor [EPC] class)

Takeda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dexilant — Competitive Intelligence Brief. https://druglandscape.com/ci/dexlansoprazole. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab